Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aeterna Zentaris (AEZS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,704
  • Shares Outstanding, K 16,440
  • Annual Sales, $ 920 K
  • Annual Income, $ -16,800 K
  • 36-Month Beta 0.91
  • Price/Sales 65.37
  • Price/Cash Flow N/A
  • Price/Book 8.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +45.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.28 +54.61%
on 11/12/18
3.92 -10.08%
on 12/04/18
+1.27 (+55.97%)
since 11/09/18
3-Month
1.29 +173.26%
on 10/30/18
3.92 -10.08%
on 12/04/18
+1.85 (+109.82%)
since 09/11/18
52-Week
1.12 +214.73%
on 04/04/18
3.92 -10.08%
on 12/04/18
+1.33 (+60.23%)
since 12/11/17

Most Recent Stories

More News
Aeterna Zentaris (AEZS) Stock Moves -0.54%: What You Should Know

Aeterna Zentaris (AEZS) closed at $3.67 in the latest trading session, marking a -0.54% move from the prior day.

AEZS : 3.58 (+1.99%)
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

Is (AEZS) Outperforming Other Medical Stocks This Year?

AEZS : 3.58 (+1.99%)
Can The Uptrend Continue for Aeterna Zentaris (AEZS)?

Investors certainly have to be happy with Aeterna Zentaris Inc. (AEZS) and its short term performance.

AEZS : 3.58 (+1.99%)
4 Healthcare Stocks Taking a New Approach to Growth Trends

CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / have rallied during the last 3 trading sessions. The Select Sector SPDR Healthcare ETF (XLV) has climbed from lows of $88.83 on Thursday to as high...

IMMY : 6.43 (+18.42%)
LCI : 5.17 (-4.08%)
AEZS : 3.58 (+1.99%)
PHGI.CN : 1.010 (+4.12%)
PHGRF : 0.7556 (+5.81%)
Aeterna Zentaris (AEZS) Receives Positive CHMP Opinion of Macimorelin for Diagnosis of Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS), announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a...

AEZS.TO : 4.78 (+1.27%)
AEZS : 3.58 (+1.99%)
4 Healthcare Stocks Turning Toward Tech For New Growth

CORAL GABLES, FL / ACCESSWIRE / November 16,2018 / There's no denying the progress that the has made. The newest wave of progress,however has much to do with technology. According to analyst firm Market...

TDOC : 54.37 (+3.88%)
AEZS : 3.58 (+1.99%)
BIOS : 3.80 (+1.33%)
Consolidated Research: 2018 Summary Expectations for Western Gas Partners, LP, HCA Healthcare, DHI Group, AEterna Zentaris, Tsakos Energy Navigation, and Acme United -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Western Gas Partners, LP (NYSE:WES),...

AEZS : 3.58 (+1.99%)
ACU : 14.72 (-2.19%)
WES : 45.39 (+0.26%)
DHX : 1.69 (+0.60%)
HCA : 135.97 (+1.38%)
TNP : 3.29 (+1.23%)
Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) and Cogas Consulting, LLC have amicably resolved their dispute with Aeterna Zentaris Inc. agreeing to make a payment to Cogas Consulting, LLC in the amount...

AEZS.TO : 4.78 (+1.27%)
AEZS : 3.58 (+1.99%)
Aeterna Zentaris Soars on Macrilen(TM) Out Licensing Deal, Analysts Review and Target

NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

AEZS : 3.58 (+1.99%)
NVO : 45.73 (-0.48%)
SBBP : 4.69 (+0.43%)
Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilen(TM) in United States and Canada

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) announces that it was advised yesterday that Strongbridge BioPharma Plc has signed an agreement with Novo Nordisk A/S pursuant to which Novo Nordisk will...

AEZS.TO : 4.78 (+1.27%)
AEZS : 3.58 (+1.99%)
NVO : 45.73 (-0.48%)
SBBP : 4.69 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade AEZS with:

Business Summary

AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead...

See More

Key Turning Points

2nd Resistance Point 3.84
1st Resistance Point 3.67
Last Price 3.58
1st Support Level 3.40
2nd Support Level 3.29

See More

52-Week High 3.92
Last Price 3.58
Fibonacci 61.8% 2.85
Fibonacci 50% 2.52
Fibonacci 38.2% 2.19
52-Week Low 1.12

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar